Evidence map›Paper›PMID 41557192›Full record

ArticleJournal of gastrointestinal cancer2026

Real-world Predictors of Early Mortality and Treatment Discontinuation in HCC Patients Treated with Atezolizumab-Bevacizumab.

Palma Fedele, Matteo Landriscina, Antonio Di Stasi, Arianna Gadaleta-Caldarola, Guido Giordano, Vincenzo Emanuele Chiuri, Mariachiara Masucci, Giulia Villano, Rosaria Martina, Federica Fumai and 5 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Palma FedeleOncology Unit, "Dario Camberlingo" Hospital, Francavilla Fontana, 72021, Italy. palma.fedele@asl.brindisi.it.
Matteo LandriscinaU.O. Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Foggia, 71100, Italy.
Antonio Di StasiOncology Unit, "Sacro Cuore di Gesù" Hospital, Gallipoli, 73014, Italy.
Arianna Gadaleta-CaldarolaMedicine and Surgery, Università degli Studi di Siena, Siena, 53100, Italy.
Guido GiordanoU.O. Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Foggia, 71100, Italy.
Vincenzo Emanuele ChiuriOncology Unit, "Sacro Cuore di Gesù" Hospital, Gallipoli, 73014, Italy.
Mariachiara MasucciU.O. Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Foggia, 71100, Italy.
Giulia VillanoU.O. Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Foggia, 71100, Italy.
Rosaria MartinaOncology Unit, "Dario Camberlingo" Hospital, Francavilla Fontana, 72021, Italy.
Federica FumaiOncology Unit, "Dario Camberlingo" Hospital, Francavilla Fontana, 72021, Italy.
Giovanni SantacroceOncology Unit, "Sacro Cuore di Gesù" Hospital, Gallipoli, 73014, Italy.
Angelo NacciOncology Unit, "Dario Camberlingo" Hospital, Francavilla Fontana, 72021, Italy.
Antonella LicchettaOncology Unit, "Sacro Cuore di Gesù" Hospital, Gallipoli, 73014, Italy.
Vincenzo DadduzioOncology Unit, "Mons. A. R. Dimiccoli" Hospital, Barletta, 70051, Italy.
Gennaro Gadaleta-CaldarolaOncology Unit, "Mons. A. R. Dimiccoli" Hospital, Barletta, 70051, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide. Atezolizumab combined with bevacizumab is the current first-line standard for advanced HCC, but its performance in real-world settings warrants further exploration.

methodsWe conducted a retrospective, multicenter study involving 80 patients treated between January 2022 and January 2024 across four Italian oncology centers. The primary objectives were early mortality and treatment discontinuation. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety profile.

resultsEarly mortality occurred in 41.2% of patients. MELD score > 11 was the only independent predictor of early death (OR: 17.52, p < 0.001), while ECOG ≥ 2 did not retain significance in multivariate analysis. Treatment discontinuation was infrequent (5%), and the combination therapy was generally well tolerated.

conclusionsMELD > 11 strongly predicted early mortality in this real-world cohort, highlighting the importance of accurate liver function assessment before treatment initiation. These findings suggest that MELD may be a valuable tool in guiding therapeutic decisions for advanced HCC in routine clinical practice.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsWithholding TreatmentAgedAntibodies, Monoclonal, HumanizedFemaleHumansItalyMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabAtezolizumabBevacizumabEarly mortalityHepatocellular carcinomaMELDReal-world evidence

Identifiers

PMID41557192

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.